Bepridil and cetiedil. Vasodilators which inhibit Ca2+-dependent calmodulin interactions with erythrocyte membranes
Abstract
Two new vascular smooth muscle relaxants, bepridil and cetiedil, were found to possess specific CaM-inhibitory properties which resembled those of trifluoperazine. Trifluoperazine, bepridil, and cetiedil inhibited Ca2+-dependent 125I-CaM binding to erythrocyte membranes and CaM activation of membrane Ca2+-ATPase with IC50 values of approximately 12, approximately 17, and approximately 40 microM, respectively. This does not appear to be the result of a nonspecific hydrophobic interaction since inhibition was not observed with micromolar concentrations of many other hydrophobic agents. The predominant inhibition of binding and Ca2+-ATPase activation was competitive with respect to CaM. Bepridil and cetiedil bind directly to CaM since these drugs displaced [3H]trifluoperazine from sites on CaM. Inhibition of Ca2+-ATPase and binding by the drugs was not due to interference with the catalytic activity of this enzyme since: (a) neither inhibition of CaM-independent basal Ca2+-ATPase activity nor inhibition of proteolytically-activated Ca2+-ATPase activities were produced by these agents, and (b) no drug-induced inhibition of CaM binding was detected when membranes were preincubated with these agents but washed prior to addition of 125I-CaM. Thus, bepridil and cetiedil competitively inhibit Ca2+-dependent interactions of CaM with erythrocyte membranes, most likely by a direct interaction between these drugs and CaM. The principal clinical actions of these drugs may be explained by their interactions with CaM or CaM-related proteins leading to reduced activation of Ca2+-regulated enzymes in certain other tissues, such as myosin light chain kinase in vascular smooth muscle.
Collections
Related items
Showing items related by title, author, creator and subject.
-
VEGF immobilization and VEGFR2 trafficking and phosphorylation: in vitro and in vivo implications
Clegg, Lindsay Elizabeth Wendel; 0000-0001-8558-9341 (Johns Hopkins UniversityUSA, 2017-06-19)Modern drug development is marked by high failure rates in translation to the clinic. Further, many drugs that succeed in clinical trials work for only a fraction of patients. Systems pharmacology attempts to address these ... -
Utility of Quantitative Analysis in Drug Development and Optimization of Anti-Infective Therapy
Hiruy, Hiwot (Johns Hopkins UniversityUSA, 2015-12-15)The cornerstone of anti-infective therapy is attainment of the effective target concentration of the drug at the site of infection; achieving this goal requires integration of the pharmacokinetic and pharmacodynamics ... -
Mechanistic approaches for reactivation and elimination of latent HIV-1
Martin, Alyssa R. (Johns Hopkins UniversityUSA, 2017-02-09)Although HIV-1 can be adequately controlled by combination antiretroviral therapy (cART), it is still an incurable disease due in part to the latent reservoir that persists in resting CD4+ T cells (rCD4s). Latently infected ...